英夫利西单抗与阿达木单抗在生物制剂初治溃疡性结肠炎患者中的比较:一项丹麦全国性队列研究
该研究为丹麦全国性登记数据库的倾向性评分匹配队列研究,比较英夫利西单抗与阿达木单抗作为首个生物制剂在生物制剂初治溃疡性结肠炎患者中的有效性与安全性。结果显示阿达木单抗组全因住院率和严重感染风险更高,但手术风险无差异。
要点
- 阿达木单抗组全因住院率高于英夫利西单抗组(HR 1.84)。
- 阿达木单抗组严重感染需住院风险显著更高(HR 5.11)。
- 两组腹部手术风险无显著差异(HR 1.35)。
核心结论
- 在生物制剂初治溃疡性结肠炎成人中,阿达木单抗作为首个生物制剂较英夫利西单抗与更高的住院风险和严重感染风险相关,但手术风险无差异。
研究设计与样本
- 全国性登记数据库的倾向性评分匹配队列研究,纳入丹麦1719例15至75岁接受英夫利西单抗或阿达木单抗作为首个生物制剂的溃疡性结肠炎成人,按2:1倾向性评分匹配。
主要发现
- 阿达木单抗组较英夫利西单抗组全因住院率更高(HR 1.84;95%CI 1.18-2.85)。
- 阿达木单抗组较英夫利西单抗组溃疡性结肠炎相关住院率有更高趋势(HR 1.71;95%CI 0.95-3.07),尤其在联合免疫调节剂治疗的患者亚组中。
- 两组腹部手术风险无差异(HR 1.35;95%CI 0.62-2.94)。
- 阿达木单抗组较英夫利西单抗组严重感染需住院风险显著更高(HR 5.11;95%CI 1.20-21.80)。
临床怎么用
- 在缺乏头对头试验的情况下,该证据可帮助患者、医疗提供者、支付方和政策制定者做出知情决策,可能改善溃疡性结肠炎的医疗照护。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: This study compares the effectiveness and safety of infliximab and adalimumab in biologic-naive patients with ulcerative colitis (UC), in a nationwide register-based propensity score-matched cohort study. METHODS: From 1719 adults with UC, between ages 15 and 75 years in Denmark treated with either infliximab or adalimumab as their first biologic agent, we compared rates of all-cause hospitalization, UC-related hospitalization, major abdominal surgery, and serious infections after a variable 2:1 propensity score matching, accounting for baseline clinical characteristics, disease severity, health care utilization, and use of UC-related medications. RESULTS: As compared with infliximab-treated patients, adalimumab-treated patients had higher rate of all-cause hospitalization (hazard ratio [HR], 1.84; 95% CI, 1.18-2.85) and a trend toward higher rate of UC-related hospitalization (HR, 1.71; 95% CI, 0.95-3.07), particularly in a stratum of patients on concomitant immunomodulator therapy. However, risk of abdominal surgery (HR, 1.35; 95% CI, 0.62-2.94) was not different between the 2 treatment groups. Risk of serious infection requiring hospitalization was significantly higher in adalimumab-treated patients (HR, 5.11; 95% CI, 1.20-21.80). CONCLUSIONS: In this nationwide propensity score matched-cohort study of biologic-naive adults with UC, use of adalimumab as first-line biologic over infliximab was associated with higher risk of hospitalization and serious infections, although risk of surgery was not different. In the absence of head-to-head trials, this evidence may assist patients, health care providers, purchasers, and policy makers to make informed decisions that may improve health care in UC.
引用
- Singh S, Andersen NN, Andersson M, et al. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study. Clin Gastroenterol Hepatol. 2016. PMID: 27913244. doi:10.1016/j.cgh.2016.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。